[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ironwood Pharmaceuti (IRWD)

Ironwood Pharmaceuti (IRWD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Ironwood Pharmaceuti 100 SUMMER STREET SUITE 2300 BOSTON MA 02110 USA

www.ironwoodpharma.com Employees: 100 P: 617-621-7722 F: 617-494-0480

Sector:

Medical

Description:

Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.

Key Statistics

Overview:

Market Capitalization, $K 598,423
Enterprise Value, $K 967,643
Shares Outstanding, K 163,058
Float, K 147,894
% Float 90.70%
Short Interest, K 18,191
Short Float 11.16%
Days to Cover 10.20
Short Volume Ratio 0.44
% of Insider Shareholders 9.30%

Financials:

Annual Sales, $ 296,150 K
Annual Net Income, $ 24,020 K
Last Quarter Sales, $ 106,510 K
Last Quarter Net Income, $ 40,770 K
EBIT, $ 200,180 K
EBITDA, $ 202,060 K

Growth:

1-Year Return 502.29%
3-Year Return -65.81%
5-Year Return -70.94%
5-Year Revenue Growth -23.97%
5-Year Earnings Growth -68.35%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.24 on 05/07/26
Next Earnings Date 08/06/26
Earnings Per Share ttm 0.61
EPS Growth vs. Prev Qtr 2,500.00%
EPS Growth vs. Prev Year 271.43%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

IRWD Ratios

Ratio
Price/Earnings ttm 6.03
Price/Earnings forward 4.18
Price/Earnings to Growth N/A
Return-on-Equity % -39.65%
Return-on-Assets % 26.54%
Profit Margin % 8.11%
Debt/Equity -2.69
Price/Sales 2.03
Price/Cash Flow 14.30
Price/Book N/A
Book Value/Share -1.33
Interest Coverage 3.14
60-Month Beta 0.29
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.